This is in line with current concepts of EZH2 as a marker of “stemness” and indeed it is thought to be associated with de-differentiation in many malignancies [42], including cholangiocarcinoma (CCA) [43], and is therefore, a common target of cancer therapy research. The gene discussed is EZH2; the disease is cancer.